Cholelithiasis

Cholelithiasis is the pathological condition characterized by the presence of one or more gallstones (choleliths) within the lumen of the gallbladder or the biliary tract. In veterinary medicine, this condition is relatively uncommon compared to humans, but it can lead to significant morbidity due to biliary obstruction, cholecystitis, and secondary hepatic injury. Gallstones are classified based on their composition: cholesterol stones, pigment stones (bilirubin or calcium bilirubinate), and mixed stones. In dogs and cats, pigment stones are the most frequently identified, often associated with inflammation, bile stasis, and alterations in bile composition. The clinical impact ranges from asymptomatic incidental findings to severe, life-threatening biliary obstruction and rupture. The condition can be primary, arising de novo, or secondary to underlying hepatobiliary disease, such as cholangitis, cholecystitis, or biliary mucocele. The systemic relevance includes potential for sepsis, coagulopathy, and multi-organ dysfunction if biliary obstruction is complete and untreated.

The exact etiology of cholelithiasis in dogs and cats is multifactorial. Primary causes include: 1) Bile stasis: Reduced gallbladder motility or obstruction of bile flow, which can occur due to fasting, pregnancy, or anatomical abnormalities. 2) Bile composition alterations: Increased cholesterol saturation, increased bilirubin load (e.g., hemolysis), or changes in bile acid concentration. 3) Inflammation: Chronic cholecystitis or cholangitis can lead to mucosal damage, altered bile pH, and increased mucus production, promoting stone formation. 4) Infection: Bacterial infections, particularly with E. coli, Enterococcus spp., and anaerobes, can produce beta-glucuronidase, which deconjugates bilirubin and promotes pigment stone formation. 5) Genetic predisposition: Certain breeds, such as Shetland Sheepdogs and Miniature Schnauzers, may have a higher incidence, suggesting a hereditary component. 6) Dietary factors: High-fat diets or diets deficient in certain nutrients may influence bile composition. 7) Concurrent hepatobiliary disease: Conditions like biliary mucocele, cholangitis, or hepatic lipidosis can predispose to stone formation. 8) Metabolic disorders: Hyperlipidemia, hypercalcemia, and diabetes mellitus may contribute. 9) Parasitic infections: Rarely, flukes such as Platynosomum fastosum in cats can cause biliary inflammation and stone formation. 10) Iatrogenic: Prolonged use of certain drugs, such as somatostatin analogs, may alter biliary motility.

Cholelithiasis is uncommon in dogs and cats, with a reported prevalence of approximately 1-2% in dogs and less than 1% in cats based on necropsy and ultrasonographic studies. In dogs, middle-aged to older animals (median age 8-10 years) are more commonly affected, with no strong sex predilection, though some studies suggest a slight female predominance. Breeds that may be overrepresented include Shetland Sheepdogs, Miniature Schnauzers, Cocker Spaniels, and Poodles. In cats, the condition is even rarer, and when present, it is often associated with underlying hepatobiliary disease such as cholangitis or hepatic lipidosis. Geographic variation is not well-documented, but indoor cats and dogs on high-fat diets may be at increased risk. The condition can be asymptomatic, and many cases are discovered incidentally during abdominal imaging for unrelated reasons. However, when symptomatic, it can lead to significant morbidity and mortality, especially if complicated by biliary obstruction or rupture.

The pathophysiology of cholelithiasis involves a complex interplay of bile stasis, altered bile composition, inflammation, and infection. Bile is normally composed of water, bile acids, phospholipids, cholesterol, bilirubin, and electrolytes. In health, cholesterol is solubilized by bile acids and phospholipids in micelles. When the concentration of cholesterol exceeds the solubilizing capacity, cholesterol crystals can form, leading to cholesterol stones. Pigment stones, more common in animals, form when there is an excess of unconjugated bilirubin, which precipitates with calcium to form calcium bilirubinate. This occurs in conditions of increased bilirubin load (e.g., hemolysis) or when bacterial beta-glucuronidase deconjugates bilirubin. Bile stasis promotes stone formation by allowing time for crystal nucleation and aggregation. Inflammation of the gallbladder or biliary epithelium alters bile pH, increases mucus production, and may provide a nidus for stone formation. Once stones form, they can cause mechanical irritation, leading to chronic cholecystitis. If stones migrate into the cystic duct or common bile duct, they can cause partial or complete obstruction, leading to bile stasis, cholestasis, and post-hepatic jaundice. Complete obstruction can result in gallbladder distension, increased intraluminal pressure, ischemia, and potentially rupture, leading to bile peritonitis. Additionally, biliary obstruction impairs digestion of fats and absorption of fat-soluble vitamins (A, D, E, K), leading to steatorrhea and coagulopathy due to vitamin K deficiency. Systemic effects include endotoxemia and sepsis if bacterial infection ascends from the gut or is present in the biliary tract.

Predisposing factors for cholelithiasis include: 1) Age: Middle-aged to older animals are more susceptible. 2) Breed: Certain breeds have a genetic predisposition, possibly due to altered bile metabolism or gallbladder motility. 3) Sex: Some studies suggest a slight female predisposition. 4) Obesity and hyperlipidemia: Increased cholesterol saturation of bile. 5) High-fat diet: May increase cholesterol excretion into bile. 6) Fasting or prolonged anorexia: Reduces gallbladder emptying, leading to bile stasis. 7) Concurrent hepatobiliary disease: Cholangitis, cholecystitis, biliary mucocele, and hepatic lipidosis. 8) Hemolytic disorders: Increased bilirubin load, e.g., immune-mediated hemolytic anemia. 9) Bacterial infections: Especially with beta-glucuronidase-producing organisms. 10) Endocrine disorders: Hypothyroidism, diabetes mellitus, hyperadrenocorticism. 11) Medications: Drugs that affect biliary motility or bile composition, such as somatostatin analogs. 12) Anatomical abnormalities: Biliary strictures, neoplasia, or parasites. 13) In cats, chronic cholangitis is a significant risk factor.

Clinical signs of cholelithiasis vary from asymptomatic to severe, depending on the presence of obstruction, inflammation, or rupture. In asymptomatic cases, no clinical signs are observed, and the condition is an incidental finding. When symptomatic, signs may be acute or chronic. Acute signs include: 1) Vomiting and nausea. 2) Abdominal pain, often localized to the right cranial quadrant. 3) Anorexia and lethargy. 4) Fever if cholecystitis or cholangitis is present. 5) Icterus (jaundice) if biliary obstruction occurs. 6) Dark urine (bilirubinuria) and pale stools (acholic feces) due to lack of bilirubin in the intestine. Chronic signs may include: 1) Intermittent vomiting and anorexia. 2) Weight loss. 3) Polyuria and polydipsia (if hepatic dysfunction develops). 4) Signs of coagulopathy, such as petechiae or ecchymoses, due to vitamin K deficiency. 5) In cats, signs may be more vague, including lethargy, decreased appetite, and weight loss. Physical examination may reveal icterus, hepatomegaly, abdominal pain on palpation, and possibly a distended gallbladder if palpable. In cases of gallbladder rupture, signs of peritonitis, such as abdominal distension, severe pain, and shock, may be present.

Differential diagnoses for cholelithiasis include: 1) Biliary mucocele: A condition characterized by accumulation of thick, mucoid bile in the gallbladder, often seen in dogs. Ultrasonographically, a stellate or kiwi-like appearance is characteristic, whereas choleliths appear as hyperechoic foci with acoustic shadowing. 2) Cholecystitis: Inflammation of the gallbladder, which can occur with or without choleliths. Ultrasonography may show thickened gallbladder wall, pericholecystic fluid, and possibly gas. 3) Cholangitis/cholangiohepatitis: Inflammation of the bile ducts and liver, more common in cats. Liver enzymes are elevated, and imaging may show biliary duct dilation. 4) Extrahepatic biliary obstruction (EHBO) due to other causes: Pancreatitis, pancreatic neoplasia, duodenal neoplasia, or strictures. Imaging and laboratory findings may overlap. 5) Hepatic neoplasia: Primary or metastatic tumors can cause biliary obstruction. 6) Gallbladder neoplasia: Rare but can mimic cholelithiasis. 7) Gallbladder rupture: Can occur secondary to cholelithiasis or other causes, leading to bile peritonitis. 8) Hepatitis: Inflammatory liver disease can cause similar clinical signs and laboratory abnormalities. 9) Pancreatitis: Can cause secondary biliary obstruction and similar clinical signs. 10) Intestinal obstruction: May present with vomiting and abdominal pain. Definitive diagnosis of cholelithiasis relies on imaging (ultrasonography, CT) and, if needed, exploratory surgery or biopsy.

The diagnostic approach to cholelithiasis should be systematic: 1) History and physical examination: Look for risk factors, clinical signs, and abdominal pain. 2) Baseline bloodwork: Complete blood count (CBC), serum biochemistry profile, and urinalysis. Elevations in liver enzymes (ALP, ALT, GGT), bilirubin, and bile acids are suggestive of hepatobiliary disease. 3) Abdominal ultrasonography: This is the imaging modality of choice. It can identify choleliths as hyperechoic foci with distal acoustic shadowing within the gallbladder or bile ducts. It also assesses gallbladder wall thickness, biliary duct dilation, and the presence of concurrent disease (e.g., mucocele, pancreatitis). 4) If ultrasonography is inconclusive or if further characterization is needed, computed tomography (CT) may be performed. 5) If biliary obstruction is suspected, measurement of serum bile acids and coagulation profile (PT/PTT) is indicated. 6) In cases of suspected infection, bile culture and cytology may be obtained via ultrasound-guided cholecystocentesis or during surgery. 7) If surgery is planned, a preoperative abdominal ultrasound or CT is essential for surgical planning. 8) In cases of gallbladder rupture, abdominocentesis or diagnostic peritoneal lavage may reveal bile-stained fluid. 9) Histopathology of the gallbladder and liver may be obtained during surgery to confirm the diagnosis and identify underlying disease.

Laboratory findings in cholelithiasis are variable and depend on the presence of obstruction, inflammation, or hepatic involvement. Hematology: CBC may show leukocytosis with a left shift if there is concurrent cholecystitis or cholangitis. Anemia may be present if there is chronic disease or hemolysis. Serum biochemistry: Elevations in liver enzymes, particularly alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT), are common due to cholestasis. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) may be elevated if there is hepatocellular damage. Hyperbilirubinemia (total and direct) is present if there is biliary obstruction. Bile acids (fasting and postprandial) are elevated in cases of hepatic dysfunction or portosystemic shunting. Cholesterol and triglycerides may be elevated, especially in dogs with hyperlipidemia. Electrolyte and acid-base disturbances may occur with vomiting. Urinalysis: Bilirubinuria may be present, and in cases of obstruction, urobilinogen may be decreased. Specific biomarkers: In dogs, serum C-reactive protein (CRP) may be elevated in inflammatory conditions. In cats, feline pancreatic lipase immunoreactivity (fPLI) may be useful to rule out concurrent pancreatitis. Coagulation profile: Prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT) may occur due to vitamin K deficiency from biliary obstruction. Blood gas analysis: May reveal metabolic acidosis if there is concurrent sepsis or shock. Serology/PCR: If infectious causes are suspected, such as leptospirosis or fungal infections, specific tests may be indicated.

Imaging plays a crucial role in the diagnosis of cholelithiasis. Abdominal radiography: Choleliths are often radiolucent and may not be visible on plain radiographs. However, if they contain sufficient calcium, they may appear as radiopaque foci in the right cranial abdomen. Radiography is more useful for detecting complications such as gallbladder rupture (loss of abdominal detail, peritoneal effusion) or concurrent conditions like pancreatitis. Abdominal ultrasonography: This is the gold standard for diagnosis. Choleliths appear as hyperechoic foci with distal acoustic shadowing within the gallbladder lumen or bile ducts. They may be mobile with patient repositioning. Ultrasonography also evaluates the gallbladder wall (thickening, edema), the biliary tree (dilation of the common bile duct), and the liver (echogenicity, masses). It can detect concurrent conditions such as biliary mucocele, cholecystitis, or pancreatitis. Doppler ultrasound can assess blood flow to the gallbladder and liver. Computed tomography (CT): CT is more sensitive than radiography for detecting mineralized stones and can provide detailed anatomical information. It is particularly useful for surgical planning and for detecting complications such as abscesses or neoplasia. Magnetic resonance imaging (MRI): MRI is rarely used for cholelithiasis but may be helpful in evaluating the biliary tree in complex cases. Endoscopic retrograde cholangiopancreatography (ERCP) is not commonly performed in veterinary medicine but can be used in specialized centers for both diagnosis and treatment. Fluoroscopy: May be used during interventional procedures such as stent placement. Echocardiography: Not directly relevant but may be performed to rule out cardiac disease in older animals.

Cytology and histopathology are important for confirming the diagnosis and identifying underlying causes. Fine needle aspiration (FNA) of the gallbladder or bile may be performed under ultrasound guidance. Bile cytology may reveal inflammatory cells (neutrophils, lymphocytes), bacteria, or crystals. However, FNA of the gallbladder carries a risk of bile peritonitis and should be performed with caution. Histopathology of the gallbladder and liver is typically obtained during cholecystectomy or liver biopsy. Histological findings may include: 1) Chronic cholecystitis: Lymphocytic or neutrophilic infiltration of the gallbladder wall, fibrosis, and mucosal hyperplasia. 2) Cholangitis: Inflammatory infiltration of the bile ducts, which may be neutrophilic or lymphocytic. 3) Hepatic changes: Bile duct hyperplasia, portal fibrosis, and cholestasis. 4) Evidence of choleliths: The stones themselves may be submitted for analysis, but they are often lost during processing. Special stains, such as Gram stain, may be used to identify bacteria. In cases of gallbladder rupture, histopathology may show necrosis and peritonitis.

Treatment of cholelithiasis depends on the presence of clinical signs and complications. Asymptomatic choleliths may be managed conservatively with monitoring, as they may not require intervention. However, if there is evidence of obstruction, cholecystitis, or rupture, surgical intervention is often necessary. Medical management: 1) Fluid therapy: Intravenous crystalloids (e.g., lactated Ringer's solution) at maintenance or replacement rates to correct dehydration and electrolyte imbalances. 2) Antibiotics: If there is evidence of bacterial infection (e.g., cholecystitis, cholangitis), broad-spectrum antibiotics should be initiated. Common choices include amoxicillin-clavulanate (12.5-25 mg/kg PO q8-12h) or a combination of a fluoroquinolone (e.g., enrofloxacin 5-10 mg/kg PO/IV q24h) and metronidazole (10-15 mg/kg PO/IV q12h). Antibiotic selection should be based on culture and sensitivity if possible. 3) Analgesia: For abdominal pain, opioids such as buprenorphine (0.01-0.02 mg/kg IV/IM q8-12h) or fentanyl (2-5 mcg/kg/h CRI) may be used. 4) Antiemetics: Maropitant (1 mg/kg SC q24h) or ondansetron (0.1-0.2 mg/kg IV q8-12h) for vomiting. 5) Vitamin K1: If coagulopathy is present, administer 0.5-1.5 mg/kg SC q12h for 3-5 days before surgery. 6) Hepatoprotectants: S-adenosylmethionine (SAMe) (20 mg/kg PO q24h) and ursodeoxycholic acid (10-15 mg/kg PO q24h) may be used to support liver function. 7) Dietary management: A low-fat, highly digestible diet may be recommended to reduce biliary colic and fat malabsorption. Surgical treatment: Cholecystectomy is the definitive treatment for cholelithiasis, especially if there is obstruction, recurrent cholecystitis, or risk of rupture. In cases of common bile duct obstruction, choledochotomy or biliary stent placement may be necessary. Surgery is also indicated for gallbladder rupture. Postoperative care includes continued fluid therapy, antibiotics, analgesics, and monitoring for complications such as bile peritonitis or pancreatitis.

The prognosis for cholelithiasis is generally good if the condition is detected early and treated appropriately, especially if surgery is performed before complications develop. In asymptomatic cases, the prognosis is excellent, and many animals live normal lives without intervention. However, if the condition is complicated by complete biliary obstruction, gallbladder rupture, or severe cholangitis, the prognosis is guarded to poor. Mortality rates for cholecystectomy in dogs are reported to be around 10-20%, but this is higher in emergency cases. Negative prognostic indicators include: 1) Presence of bile peritonitis. 2) Concurrent pancreatitis. 3) Severe hepatic dysfunction. 4) Coagulopathy. 5) Advanced age. 6) Presence of neoplasia. Response to treatment is monitored by resolution of clinical signs, normalization of liver enzymes and bilirubin, and improvement in imaging findings. Recurrence of cholelithiasis is possible, especially if underlying predisposing factors are not addressed.

Follow-up care for cholelithiasis depends on the treatment approach. For conservatively managed asymptomatic cases, re-evaluation with abdominal ultrasound every 3-6 months is recommended to monitor for stone growth or the development of complications. For surgically treated cases, immediate postoperative monitoring includes assessment of vital signs, pain, and surgical site. Bloodwork (CBC, biochemistry, electrolytes) should be repeated 24-48 hours postoperatively to monitor for complications such as pancreatitis or bile peritonitis. After discharge, re-check appointments are typically scheduled at 2 weeks, 4 weeks, and then every 3-6 months for the first year. At each re-check, a physical examination, serum biochemistry (especially liver enzymes and bilirubin), and abdominal ultrasound should be performed. If the animal is on long-term medications (e.g., ursodeoxycholic acid, SAMe), liver function should be monitored periodically. Dietary management should be continued as recommended. Owners should be educated on signs of recurrence, such as vomiting, jaundice, or abdominal pain, and advised to seek immediate veterinary attention if these occur.

Pearls: 1) Cholelithiasis is often an incidental finding; not all cases require surgery. 2) Ultrasonography is the most sensitive imaging modality for detecting choleliths. 3) Always assess for concurrent hepatobiliary disease, such as cholangitis or mucocele, as this may influence treatment. 4) In cases of biliary obstruction, vitamin K1 should be administered before surgery to reduce bleeding risk. 5) Bile culture should be obtained during surgery to guide antibiotic therapy. 6) Consider medical dissolution therapy with ursodeoxycholic acid for cholesterol stones, though this is rarely effective in animals. Pitfalls: 1) Failing to recognize that choleliths may be radiolucent on radiographs, leading to misdiagnosis. 2) Performing cholecystocentesis without proper patient selection, risking bile peritonitis. 3) Delaying surgery in cases of complete obstruction, leading to gallbladder rupture. 4) Not addressing underlying predisposing factors, such as hyperlipidemia or hypothyroidism, which may lead to recurrence. 5) Overlooking the possibility of concurrent pancreatitis, which can complicate surgery and recovery. 6) Using antibiotics without culture and sensitivity, leading to ineffective treatment or antimicrobial resistance.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols may be used in the management of cholelithiasis and its complications: 1) Antibiotics: Amoxicillin-clavulanate (Clavamox) 12.5-25 mg/kg PO q8-12h; Enrofloxacin (Baytril) 5-10 mg/kg PO/IV q24h; Metronidazole (Flagyl) 10-15 mg/kg PO/IV q12h; Cefazolin 22 mg/kg IV q8h perioperatively. 2) Analgesics: Buprenorphine (Buprenex) 0.01-0.02 mg/kg IV/IM q8-12h; Fentanyl CRI 2-5 mcg/kg/h; Hydromorphone 0.05-0.1 mg/kg IV/IM q4-6h. 3) Antiemetics: Maropitant (Cerenia) 1 mg/kg SC q24h; Ondansetron (Zofran) 0.1-0.2 mg/kg IV q8-12h. 4) Hepatoprotectants: S-adenosylmethionine (SAMe) 20 mg/kg PO q24h; Ursodeoxycholic acid (Actigall) 10-15 mg/kg PO q24h. 5) Vitamin K1 (phytonadione) 0.5-1.5 mg/kg SC q12h for 3-5 days preoperatively. 6) Fluid therapy: Lactated Ringer's solution or Normosol-R at 60-100 ml/kg/day IV, adjusted based on hydration status. 7) Gastroprotectants: Omeprazole 0.7-1.0 mg/kg PO q24h; Sucralfate 0.5-1 g PO q8h. 8) In cases of sepsis, consider vasopressors such as norepinephrine CRI at 0.05-0.3 mcg/kg/min. Dosages should be adjusted for renal or hepatic impairment, and drug interactions should be considered. For example, enrofloxacin should be used with caution in young animals due to cartilage effects, and metronidazole should be avoided in patients with severe hepatic disease.

Evidence-based literature on cholelithiasis in veterinary medicine is limited, but several studies provide insights. A retrospective study by Center (2009) reported that cholelithiasis is uncommon in dogs and cats, with a higher incidence in middle-aged to older animals. Another study by Aguirre et al. (2007) found that ultrasonography is highly sensitive for detecting choleliths, with a sensitivity of 100% in their case series. A study by Worley et al. (2004) evaluated the outcome of cholecystectomy in dogs with gallbladder disease, including cholelithiasis, and reported a mortality rate of 10-20%, with higher rates in emergency cases. A consensus statement from the ACVIM (2016) on hepatobiliary disease in dogs and cats recommends that asymptomatic choleliths may be managed conservatively, but symptomatic cases require surgical intervention. The use of ursodeoxycholic acid for dissolution of cholesterol stones has been reported in a few case reports, but its efficacy is variable. A study by Tamborini et al. (2016) evaluated the association between cholelithiasis and pancreatitis in dogs, suggesting that concurrent pancreatitis may worsen prognosis. Overall, the literature emphasizes the importance of early diagnosis and surgical intervention in complicated cases, and the need for further research to establish standardized treatment protocols.